Multitreatment radioimmunotherapy (RIT) mice bearing OVCAR3 xenografts. Doses were given at days 0, 7, 14, 21, 28, and 35. (A) Tumor volume vs. time after radioimmunotherapy. (B) Kaplan–Meier survival plots (n = 8 for all groups). Tumor growth curve for radioimmunotherapy-targeted group was statistically significant (P = 0.043) compared with controls. Survival curve for targeted radioimmunotherapy was statistically significant (P < 0.0001) compared with controls.